Cite
MLA Citation
James Spicer et al.. “362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A387. http://access.bl.uk/ark:/81055/vdc_100144722195.0x000004